ARS PHARMACEUTICALS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.945 USD | +1.65% |
|
-1.22% | +62.77% |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 799.9 | 526.1 | 852.7 | - | - |
| Enterprise Value (EV) 1 | 525.5 | 526.1 | 711.3 | 708.4 | 628.8 |
| P/E ratio | -9.8 x | -9.61 x | -14.4 x | -23.2 x | 22.3 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | 608 x | 17,535 x | 137 x | 9.98 x | 4.02 x |
| EV / Revenue | 399 x | 17,535 x | 115 x | 8.29 x | 2.97 x |
| EV / EBITDA | - | - | - | - | - |
| EV / FCF | - | - | - | - | - |
| FCF Yield | - | - | - | - | - |
| Price to Book | - | - | - | - | - |
| Nbr of stocks (in thousands) | 93,770 | 95,997 | 96,895 | - | - |
| Reference price 2 | 8.530 | 5.480 | 8.800 | 8.800 | 8.800 |
| Announcement Date | 3/23/23 | 3/21/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | 1.316 | 0.03 | 6.21 | 85.45 | 211.9 |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | - | -35.52 | -67.52 | -76.94 | -36.88 | 67.76 |
| Operating Margin | - | -2,698.78% | -225,066.67% | -1,238.99% | -43.16% | 31.98% |
| Earnings before Tax (EBT) 1 | - | -34.68 | -54.36 | -67.18 | -30.35 | 79.52 |
| Net income 1 | -20.24 | -34.68 | -54.36 | -63.29 | -40.9 | 40.06 |
| Net margin | - | -2,635.41% | -181,216.67% | -1,019.23% | -47.86% | 18.91% |
| EPS 2 | -0.8300 | -0.8700 | -0.5700 | -0.6100 | -0.3800 | 0.3950 |
| Free Cash Flow | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 10/6/22 | 3/23/23 | 3/21/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 0.02 | 0.01 | - | - | - | 1 | 1 | 4.34 | 2.8 | 11 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -15.44 | -18.71 | -20.6 | -17.98 | -57.29 | -13.19 | -11.6 | -22.58 | -29.56 | - | - |
| Operating Margin | - | -93,565% | -206,030% | - | - | - | -1,160.1% | -2,258.1% | -681.18% | - | - |
| Earnings before Tax (EBT) 1 | -14.43 | -14.96 | -17.37 | -14.87 | -7.168 | -10.29 | -8.917 | -20.42 | -27.56 | - | - |
| Net income 1 | -14.43 | -14.96 | -17.37 | -14.87 | -7.168 | -10.29 | -12.36 | -18.16 | -22.48 | - | - |
| Net margin | - | -74,805% | -173,700% | - | - | - | -1,235.85% | -1,815.85% | -517.93% | - | - |
| EPS 2 | -0.0900 | -0.1600 | -0.1800 | -0.1600 | -0.0700 | -0.1100 | -0.1150 | -0.1750 | -0.2200 | -0.2500 | -0.1800 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/23/23 | 5/15/23 | 8/10/23 | 11/9/23 | 3/21/24 | 5/9/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | - | 274 | - | 141 | 144 | 224 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex | - | 0.2 | - | - | - | - |
| Capex / Sales | - | 15.12% | - | - | - | - |
| Announcement Date | 10/6/22 | 3/23/23 | 3/21/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
8.8
USD
Average target price
19
USD
Spread / Average Target
+115.91%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +62.77% | 853M | |
| +69.38% | 62.86B | |
| -0.74% | 41.38B | |
| +45.66% | 40.38B | |
| -10.72% | 27.64B | |
| +14.20% | 26.46B | |
| -22.50% | 18.9B | |
| +4.76% | 12.67B | |
| +23.73% | 12.27B | |
| +28.05% | 12.07B |
- Stock Market
- Equities
- SPRY Stock
- Financials ARS Pharmaceuticals, Inc.
